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Abstract  
Hirschsprung disease (HSCR), or congenital aganglionosis, is 
characterized by a contiguous lack of enteric neurons in variable segments of the 
gut. Both coding and non-coding mutations in the receptor tyrosine kinase RET 
are the major genetic drivers of the disease, although all disease causing 
mutations in RET have not yet been identified. A prior Genome Wide Association 
Study (GWAS) using 220 HSCR trios identified 38 common single nucleotide 
polymorphisms (SNPs) that are significantly associated with the disease and are 
located in non-coding regions at the RET locus. Eight of these SNPs disrupt 
known RET transcription factor binding sites in the human neuroblastoma cell 
line, SK-N-SH, and are located within enhancer elements. Three of these eight 
SNPs show differential enhancer activity between the non-risk and disease 
associated (risk) alleles, or an allelic difference. I sought to determine how many 
of the remaining 30 SNPs displayed enhancer activity and allelic differences by 
using a dual in vitro luciferase reporter assay in SK-N-SH cells. My studies 
revealed that 28 SNPs had enhancer activity while seven of those displayed allelic 
differences. The SNPs that showed an allelic difference and affected enhancer 
activity potentially disrupt binding sites for PAX3, MZF1, ZNF263, and 
Myb/Mybl1.  Therefore, the genetic risk of HSCR susceptibility at RET is 
conferred by allelic differences at at least 10 enhancer elements, demonstrating 
the high degree of intra-locus risk heterogeneity. 
 
Mentor/Principal Investigator: Aravinda Chakravarti, Ph.D. 
Advisor: Robert D. Horner, Ph.D. 
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1. Introduction 
Hirschsprung disease (HSCR), or congenital aganglionosis, is 
characterized by a failure of enteric neural crest-derived intestinal ganglion cells 
to fully migrate, proliferate, or differentiate through the length of the fetal 
intestines during development.1 The lack of precursor cells leads to an absence of 
neurons in the myenteric and submucosal plexus along variable but contiguous 
lengths of the gastrointestinal tract. Without viable neurons, the affected length 
of bowel is non-functional and must be surgically resected. 1   
HSCR is classified into three distinct forms: short-segment (S-HSCR; 
aganglionosis up to the upper sigmoid colon), long-segment (L-HSCR; 
aganglionosis up to the splenic fixture and beyond), and total colonic 
aganglionosis (TCA; aganglionosis affecting the entirety of the large intestine). S-
HSCR accounts for about 80% of cases, while L-HSCR and TCA account for 15% 
and 5% respectively.1  Additionally, in less than 1% of cases, total intestinal 
agaglianosis (TIA; aganglionosis of the entire large intestine and also extending 
into the small intestine) occurs and is often lethal.2,3  Since HSCR is a congenital 
disease, risk alleles and disease susceptibility are potentially evolutionarily 
maintained if carriers have a selective advantage. It is thought that HSCR and the 
associated slower bowel motility may provide a substantial survival advantage in 
communities where diarrheal illness was a major cause of death. 3  Otherwise, 
affected individuals would have been unlikely to survive to reproductive age 
before surgical intervention was possible, and therefore the risk alleles would not 
have remained in the gene pool. 
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HSCR is frequently associated with other malformation syndromes and 
chromosomal abnormalities (e.g. Waardenburg syndrome, Smith-Lemili-Opitz 
syndrome type II, trisomy 21, and interstitial deletion of chromosome 13q. 2,4  
Hirschsprung Disease is the major genetic cause of functional intestinal 
obstruction in neonates with an incidence of ~1 per 5,000 live births. However, 
the incidence varies significantly among ethnic groups (1.5, 2.1, and 2.8 per 
10,000 live births in Caucasians, African-Americans, and Asians, respectively). 1  
There is also a marked sex bias and males are four times more likely than females 
to develop HSCR. 1   
During fetal development, the intestinal tract is innervated anteriorly to 
posteriorly due to a wave of morphogenetic changes. 5  The migration and 
differentiation of intramural ganglion cells can be attributed to a highly regulated 
and complex series of gene expression and interactions. The complex regulation 
of gut innervation is evident by the number of genes implicated in Hirschsprung 
disease. Previous studies have identified 14 genes with mutations in HSCR: RET, 
GDNF, NRTN, SOX10, EDNRB, EDN3, ECE1, ZFHX1B, PHOX2B, TCF4, 
KIAA1279, GRFA1, PSPN, L1CAM. 3,6  However, of these 14 genes, RET (a 
receptor tyrosine kinase, rearranged during transfection) is the major gene 
containing deficiency alleles, or alleles resulting in reduced expression, in >80% 
of cases. 6  Studies have shown that expression of HSCR-associated RET receptors 
lead to apoptosis, which may contribute to the absence of enteric neurons. 7   
 HSCR can be either familial or sporadic. Approximately 20% of cases are 
familial, while the remaining 80% are sporadic. 2  Both forms may arise from a 
Mendelian mode of inheritance (both dominant and recessive with reduced 
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penetrance) as well as more complex, non-Mendelian modes of inheritance. 3  
Mutations in RET are highly associated with the development of HSCR, but only 
50% of familial and 15-20% of sporadic Hirschsprung cases have previously been 
reported to have causal mutations. 2  Less than 30% of HSCR cases overall have 
coding mutations in any of the genes known to be associated with the disease. 6  A 
contributing factor to the difficulty in identifying all genetic causes of HSCR is 
that generally, complex diseases, such as HSCR, are not caused by a single rare 
coding variant. Rather, a multitude of common variants with small effect sizes 
leads to the disease. 3  Multiple mutations having a compounding effect might 
also explain the varying degrees of severity found in HSCR.  
However, because so many genes are associated with the disease, and 
many disease associated single nucleotide polymorphisms (SNPs) are present in 
and around these loci, a comprehensive map of all such regulatory SNPs is 
essential. A complete map of regulatory elements that are associated with HSCR 
would greatly increase the ability to diagnostically predict disease risk as well as 
contribute to a better understanding of how HSCR manifests during embryotic 
gut development. Since the majority of causal SNPs have been found in the RET 
gene, there is an ongoing effort by our lab to identify every causal SNP in the RET 
locus. Causal SNPs in non-coding DNA tend to lie within a regulatory region 
(such as an enhancer) and potentially disrupt important transcription factor (TF) 
binding sites, therefore dysregulating gene expression and hence function.  
 To identify SNPs associated with the development of HSCR, a Genome 
Wide Association Study (GWAS) was performed using 220 HSCR trios (an 
affected individual and both of their unaffected parents).8  Thirty-eight common 
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SNPs (minor allele frequency >10%) were found at the RET locus and were 
associated with HSCR at a genome wide significance level (p≤5x10-8). In addition 
to the associated SNPs, epigenomic data was also used to predict putative 
enhancer regions. DNaseI hypersensitivity, monomethylation of Histone 3 Lysine 
4 (H3K4me1), and acetylation of Histone 3 Lysine 27 (H3K27ac) are all 
epigenetic markers that are a strong predictor of active enhancers. 9-11  The NIH 
Roadmap Project has compiled data for these marks in human fetal gut tissue, 
which were used in this study to mark putative gut enhancers. 12  Of the 38 SNPs, 
eight disrupt a known transcription factor (TF) binding site in a human 
neuroblastoma cell line, SK-N-SH. 13  The remaining 30 SNPs do not disrupt a 
known TF binding site but do overlap H3K4me1, H3K27ac, and/or DNaseI 
hypersensitivity regions in the fetal gut and, thus, may disrupt a yet 
uncharacterized biding site in an enhancer. These remaining 30 SNPs were 
assayed in an in vitro enhancer assay to determine first, if they are located in 
enhancer regions, and second, if the risk variant disrupts the function of the 
region.  We found 28 of these SNPs are located in an enhancer element, and 
seven showed allelic differences in activity. Since all of the tested regions are 
present in and around the RET gene, and the SNPs are significantly associated 
with HSCR, it is highly likely they are regulatory elements controlling the 
expression of RET.  We then looked at the 13 haplotypes (>1% frequency in the 
population) containing various risk and non-risk alleles for these 10 SNPS with 
allelic difference (seven from this study and three previously characterized) to 
ascertain variation in HSCR risk across variant haplotypes. Three of the 
haplotypes had an significant effect on risk of the disease compared to an almost 
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risk allele free haplotype and, furthermore, the haplotype containing all 10 risk 
alleles had an 11-fold increase in risk compared to control. In this study, we have 
generated a comprehensive functional map of all known disease associated SNPs 
at a locus for a complex disease and have shown that combinatorial effects from 
multiple enhancer variants are critical for a complete accounting of disease risk. 
 
2. Materials and Methods 
Polymerase Chain Reaction (PCR) 
The UCSC Genome browser was used to obtain DNA sequence information 
for the region surrounding each SNP. DNA sequences approximately 500 bp long 
containing the SNP were identified (Appendix). Takara Clontech InFusion Primer 
Design and Primer3 were used to design primers with homology regions to the 
pGL4.23 [luc2/minP] plasmid (Appendix). All PCR reactions were 30 cycles long 
and used Phusion High-Fidelity DNA Polymerase (New England BioLabs Inc., 
Ipswitch, MA). All DNA samples came from the National Human Genome 
Research Institute’s HapMap Project 14  (Coriell Cell Repositories, Camden, NJ) 
(Appendix). We carefully selected genomic DNA samples for each construct to 
minimize any additional variation between the non-risk and the risk allele since 
we wished to study each genetic variant in isolation. Following successful 
amplification, the PCR products were cleaned up by Qiaquick PCR purification 
Kit (Qiagen, Hilden, Germany). 
Cloning  
The PCR amplified region of interest was inserted by homology cloning 
into the cut pGL4.23 [luc2/minP] vector using an InFusion Cloning kit (Takara 
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Bio, Mountain View, CA). The InFusion Cloning protocol was followed. For this 
protocol, the desired vector was first linearized using a double digest. In this case, 
pGL4.23[luc2/minP] was linearized with KpnI-HF and XhoI (New England 
Biolabs, Ipswitch, MA). The primers designed for PCR amplifies the DNA 
sequence of interest, and includes 15 bp on each end of the PCR product that is 
homologous to the linearized ends of the vector. The InFusion enzyme recognizes 
the ends of the PCR products and the ends of the linearized vector and induces 
homologous recombination, resulting in a circular vector with the correct insert.  
Following the cloning reaction, the vectors were transformed into Stellar 
Competent Cells (an E. coli HST08 strain). Transformed bacterial cells were 
plated on Luria Bertani (LB) agar plates containing ampicillin at 100µg/ml 
concentration. Cells were allowed to grow overnight, following which individual 
colonies were selected for a bacterial colony PCR reaction. The forward 
(CCAGTGCAAGTGCAGGTGCC) and reverse (CGTAGCGCTTCATGGCTTTG) 
primers used for the colony PCR are complementary to the vector backbone and 
can detect if a fragment of the right size has been inserted into the vector. If the 
colony was positive for an insert of the correct size, plasmid DNA was isolated 
from an overnight bacterial culture and sent for sequencing at the Johns Hopkins 
Genetics Research Core Facility using the same primers as the colony PCR 
reaction. Once sequencing confirmed the correct inserts, non-risk and risk allele 
sequences were aligned to the reference human genome assembly hg19/GRCh37 
using Sequencher (Gene Codes Corporation, Ann Arbor, MI) to check for any 
differences between the cloned sequence and the human reference sequence. We 
also checked for any additional SNPs between the two constructs as well as any 
	   7	  
additional variants that were not identified during the HAPMAP study (see 
Results). 
Cell Culture 
All assays were performed in the human neuroblastoma cell line SK-N-SH. 
The cells were grown in a media containing 500 ml DMEM (ThermoFisher 
Scientific, Waltham, MA), 50 ml Fetal Bovine Serum (ThermoFisher Scientific, 
Waltham, MA), 5 ml Pen-Strep (ThermoFisher Scientific, Waltham, MA), and 5 
ml L-Glutamine (ThermoFisher Scientific, Waltham, MA). SK-N-SH, an adherent 
cell line, was grown in 10 cm dishes, and dissociated using 0.05% Trypsin-EDTA. 
(ThermoFisher Scientific, Waltham, MA).  
Luciferase Assay 
The non-risk and risk allele containing vectors were then used for dual 
luciferase reporter assays. SK-N-SH cells were plated on a 24 well plate, allowed 
to grow to about 50% confluence (typically overnight), and then transfected with 
30 ng of a luciferase vector either containing the putative enhancer element or 
just the empty vector, and FuGene (a nonliposomal transfection reagent) 
(Promega, Madison, WI) mixed in Opti-MEM (ThermoFisher Scientific, 
Waltham, MA). Each well was also transfected with 6 ng of renilla luciferase 
vector as a transfection control. Transfected cells were allowed to grow to 90-
100% confluency (24 hours). Each assay was performed in triplicate. 
After 24 hours the media was removed and cells were washed with neutral 
phosphate buffered saline (PBS) before being lysed for 30 minutes by shaking at 
room temperature in 150 µl of Passive Lysis Buffer from a Dual Luciferase 
Reporter (DLR) Assay kit (Promega, Madison, WI). The lysate was spun down at 
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4˚C for 2 minutes to pellet any cellular debris, and then 30 µl of lysate from each 
well was plated in triplicate on a 96 well plate. A Tecan InFinite Pro workstation 
was used to perform the dual luciferase assay. The Dual-Luciferase Reporter 
Assay System protocol was followed, except each well was injected with 50 µl of 
LARII and Stop&Glo substrate for firefly and renilla luciferase respectively 
(Promega, Madison, WI).  
Gene Expression Assay 
RNA isolated from SK-N-SH cells was converted to cDNA using 
SuperScript IV Reverse Transcriptase (ThermoFisher Scientific, Waltham, MA). 
The SuperScript IV reverse transcription protocol was followed. The cDNA was 
then used with TaqMan Gene Expression assays to perform qPCR with probes 
Hs00992437_m1 (PAX3) and Hs01019337_m1 (ZNF263) with Human GAPD 
(GAPDH) Endogenous Control as an internal loading control (ThermoFisher 
Scientific, Waltham, MA).  
Haplotype Odds Risk Determination 
Once the SNPs displaying an allelic difference were determined, 
haplotypes present in a control (non-HSCR) and case (HSCR) population were 
created. Control population haplotype data was collected from the CEU, FIN, 
GBR, IBS, and TSI (total of 503 European ancestry samples) populations in the 
1000 Genomes Project 
(ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20110521/). 15  Case 
population haplotype data was collected from the 220 HSCR Trio probands from 
the HSCR GWAS 8  using Affy500K 8  and HapMap imputation 14 . The haplotypes 
were analyzed with Haploview 16  and Plink 
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(http://pngu.mgh.harvard.edu/purcell/plink). 17 Standard methods were used for 
calculation of odds ratios (OR), upper and lower confidence limits and 
significance of deviation from the null hypothesis of no association (OR = 1) by a 
χ2 statistic.18 The odds of one risk allele (CTGAACCACT) was set to 1 as there were 
no individuals with a haplotype containing no risk alleles. 
 
3. Results  
Non-Risk and Risk Vector Cloning 
The SNP IDs used throughout this study was assigned by NCBI’s dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP). After sequencing, the risk and non-risk 
vector sequences were aligned using Sequencher to ensure the correct allele was 
cloned. The non-risk and risk alleles are shown in Table 1. Some constructs had 
additional SNPs that were different in the sequences around the SNP under study 
despite efforts to minimize the background SNPs. One pair of constructs had an 
additional SNP not reported in HapMap.  
The locations of all 38 HSCR associated SNPs in this study are shown in 
Figure 1. The SNPs lay upstream and in the first intron of RET. The eight SNPs 
that disrupted known TF binding sites in SK-N-SH cells are shown in Figure 2. 
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Table 1: Non-Risk and Risk Alleles for each polymorphism tested 














1 rs788267 C T     
2 rs788263 C G rs1539291   
3 rs788262 A G     
4 rs788261 T C     
5 rs788260 G A rs186489714   
6 rs2995411 C T     
7 rs1582227 T C     
8 rs2488278 T C rs77947964   
10.11 
rs17158318/ 
rs17158320 G, C A, A     
12 rs947696 G T rs1815722   
13 rs7908085 T A rs2185791   
14 rs10900290 C T     
15 rs947690 G C     
16 rs1547930 G A     
17 rs3004258 T G     
20 rs3026703 T C     
21 rs3026707 A G 
rs3026706, 
rs3026709, 
rs4948560    
22 rs2505989 G C     
24 rs741763 G C     
25 rs2505995 A G     
26 rs2506010 C T   rs3123717 





rs28464869   
30.31 
rs2506021/ 
rs2435342 C, T T, C     
32 rs2506022 C T     
33 rs2435343 T G     
34 rs12247456 G A     
36 rs7393733 G C     
38 rs2505541 T C     
 




Figure 1: 200 kb (chr10:43,430,437-43,629,595, human genome assembly 19) region 
around the RET gene showing all 38 HSCR-associated SNPs. SNP IDs are provided in 




Figure 2: 200 kb (chr10:43,430,437-43,629,595) region around the RET gene showing 
previously tested SNPs. SNPs colored green or blue are part of enhancer elements. The 
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Enhancer Function Determination 
Luciferase assays with  ~500bp regions containing the 30 disease 
associated SNPs showed that 28 had enhancer activity, defined as >2 fold activity 
as compared to the empty vector (Figure 3). Among these 28 SNPs displaying 
enhancer activity, seven SNPs also showed a significant gene expression 
difference driven by the risk allele as compared to the non-risk allele. In 
 
 
Figure 3: Luciferase assay activity for 38 HSCR-associated SNPs. Data are reported as 
fold change relative to expression of luciferase driven by only minimal promoter vector 
(pGL4.23 empty). All regions that drive expression >2 fold as compared to empty vector 
are considered an enhancer (black serrated line). Error bars represent the standard error 
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combination with the eight previously characterized SNPs, 34 SNPS are in 
regions that showed enhancer activity and 10 had a significant allelic difference 
(Figure 4 and Figure 5). The risk alleles of SNPs 5, 9, 16, 19, 29, and 34 showed 
reduced enhancer ability compared to the non-risk allele, while the risk allele of 
SNPs 2, 4, 36, and 38 showed increased enhancer activity compared to the non-
risk allele. Thus, the results of this current study increased the number of 
regulatory elements in this locus as well as the SNPs which disrupt enhancer 
activity and might have a role in controlling the expression of RET. We now have 
a more detailed view of the regulatory universe of RET and the causal SNPs in the 
region which are associated with HSCR. 
 
 
Figure 4: 200 kb (chr10:43,430,437-43,629,595) region around the RET gene 
highlighting 30 SNPs tested in this study . SNPs shown in black are not part of an 
enhancer element. SNPs colored green showed enhancer activity in in vitro luciferase 
assays and SNPs colored blue showed significant allelic difference between the non-risk 
and risk alleles.  
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Figure 5: All SNPs (both previously and newly characterized) displaying an allelic 
difference in a 200 kb (chr10:43,430,437-43,629,595) region around the RET gene.  
 
Potential Transcription Factor Binding Disruption 
Regulatory elements, such as transcriptional enhancers, bind various 
transcription factors (TFs) for their activity. To determine the potential TFs that 
bind to enhancers that display an allelic difference we used JASPAR 19 and 
TRANSFAC20, transcription factor binding site databases. A 20 bp region 
surrounding the SNP was compared to ~900 known TF position weight matrices 
(PWMs). TF PWMs are weighted measures of experimentally determined TF 
binding sequences, which allows us to potentially predict which TF can bind a 
given DNA sequence in the absence of experimental data on that region for that 
cell line. 
The most significant matches we detected were for PAX3, MZF1, ZNF263, 
and Myb/Mybl1 (Table 2). PAX3, MZF1, and ZNF263 bind to sequences 
containing the non-risk allele of SNP 36. ZNF263 is also predicted to bind a 
sequence containing the non-risk allele of SNP 16. However, the PAX3 and MZF1 
predictions are based on few experimentally determined TF binding sequences 
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and therefore need to be verified by another method to ascertain significance; 
moreover, zinc finger binding domains are typically GC-rich sequences and 
therefore give high statistical significance owing to their rarity. Myb/Mybl1 are 
predicted to match the risk allele of SNP 2, which may contribute to the increased 
enhancer activity observed for the risk allele. There is also an ETS1 binding motif 
around the risk allele SNP 36 and a MA0055.1 binding motif around the non-risk 
allele of SNP 38, but the SNP does not disrupt the core sequence for either. 
Although it is possible that a mutation outside of the core sequence could disrupt 
binding, it is not as likely to change TF binding as a mutation within the core 
sequence is. MA0080.2 (another ETS TF) shows equal binding potential to both 
the non-risk and risk allele of SNP 36. ZID shows equal binding potential to both 
alleles of SNP 5. The Srf_secondary motif at the non-risk allele of SNP 4 doesn’t 
seem to be a real binding site since it is a secondary motif and the UA8 motif that 
matches both the risk and non-risk allele of SNP 4 belongs to an uncharacterized 
TF so further analysis (e.g. TF ChIP-seq) would need to be performed to draw any 
conclusions about that binding motif. We also detected a non-canonical binding 
motif for ATF1 near SNP 36.  Bioinformatic analysis did not predict any potential 
binding site around SNP 34.   
One way to determine if a TF could bind to an enhancer element is to 
determine if the TF is present in the cell line used for luciferase assays (SK-N-
SH). If the TF is not present in the cell, then it is unlikely that that the TF is 
affecting the enhancer activity. A gene expression assay was performed on two 
TFs: PAX3 was selected based on its known association with RET20, and ZNF263 
was selected based on its match with two of the SNPs displaying an allelic  
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Table 2: Position weight matrix (PWM) of various transcription factor 
classes 







Myb	   Myb_primary	   CAATAAACCGTTAAGTA	   2	   18	   +	   12.3	   3.72*10-­‐5	  
Mybl1	   Mybl1_primary	   CAATAAACCGTTAAGTA	   2	   18	   +	   13.1	   2.12*10-­‐5	  






unknown	   UA8	   TGAGAAGAAACAGC	   4	   17	   -­‐	   11.3	   8.68*10-­‐5	  




SRF	   Srf_secondary	   CTGAGAAAAAACAGCCT	   2	   18	   -­‐	   10.2	   5.16*10-­‐5	  
SRF	   Srf_secondary	   CCTGAGAAAAAACAGCC	   3	   19	   -­‐	   10.6	   3.45*10-­‐5	  
unknown	   UA8	   TGAGAAAAAACAGC	   4	   17	   -­‐	   12.8	   2.95*10-­‐5	  
5	  
	  
Risk	   ZBTB6	   V_ZID_01	   TGGCTCTATCATG	   5	   17	   -­‐	   15.7	   2.74*10-­‐6	  
Non-­‐Risk	   ZBTB6	   V_ZID_01	   TGGCTCCATCATG	   5	   17	   -­‐	   15.9	   2.38*10-­‐6	  




SPI1	  	   MA0080.2	   AGGAAGT	   13	   19	   +	   12.7	   6.51*10-­‐5	  
Atf1	   Atf1_secondary	   GAGTGACGAGGAAG	   5	   18	   +	   13.3	   4.68*10-­‐6	  
Non-­‐Risk	  
	  
PAX3	   V_PAX3_01	   TCGTCACTCTTAC	   1	   13	   -­‐	   5.5	   9.99*10-­‐5	  
MZF1	   V_MZF1_02	   GAGTGAGGAGGAA	   5	   17	   +	   12.1	   3.28*10-­‐5	  
SPI1	  	   MA0080.2	   AGGAAGT	   13	   19	   +	   12.7	   6.51*10-­‐5	  
ETS1	   ETS1	   CACTTCCTCCT	   10	   20	   -­‐	   13.5	   1.05*10-­‐5	  
ZNF263	   ZNF263	   CACTTCCTCCTCACT	   6	   20	   -­‐	   10.2	   6.72*10-­‐5	  
38	   Non-­‐Risk	   E-­‐box	   MA0055.1	   GGAGAGCTGGTG	   1	   12	   +	   9.7	   3.46*10-­‐5	  
The log-odds shown above used a cutoff of (stringent) p value <10-4 
 
difference. Gene expression is measured using cycle threshold (Ct) values 
determined by the number of qPCR cycles required for the fluorescent signal of 
the gene of interest to be detected. Ct values for the gene of interest are compared 
to Ct values for a housekeeping gene. The comparison is called the ∆Ct; the lower 
the ∆Ct, the higher the gene expression and vice versa. Based on the ∆Ct values 
(normalized expression compared to GAPDH gene), PAX3 is moderately 
expressed and therefore could potentially have its binding disrupted by the risk 
allele of SNP 36. However, the expression of ZNF263 is very low or absent in this 
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cell line. As noted earlier, all zinc finger TFs have a strong bias for GC rich motifs 
so it is possible that another zinc finger family protein binds instead of ZNF263 
(Table 3 and Figure 6). 
Table 3: Ct Values for GAPDH, PAX3, and ZNF263 in SK-N-SH cells 
 
Figure 6: Ct data used for ∆Ct calculation and ∆Ct for two implicated TFs (from Jaspar 
and Transfac analysis). TFs PAX3 and ZNF263 transcript levels are normalized to the 
GAPDH levels. Error bars represent the standard error of the mean.  
 
 Evolutionary Conservation 
Evolutionary conservation was an important feature for identifying 
enhancers in the past; previous studies aimed at identifying enhancers in the RET 
locus mapped putative enhancers solely via conservation 16. However, more 
recent studies have shifted away from using evolutionary conservation and 
instead focus on epigenetic modifications to inform their enhancer predictions. 
For example, the 38 SNPs tested in this study were identified partially due to 
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their epigenetic modification marks. Therefore, in order to determine how the 
new data collected during this study compared to previous knowledge of 
regulation at the RET locus, we also mapped all evolutionary conserved regions 
(70% sequence identity, >100 bp length) from 12 non-human vertebrates 
(chimpanzee, baboon, cow, pig, cat, dog, rat, mouse, chicken, zebrafish, Fugu, 
and Tetradon) using an updated conservation assembly to see which of the 38 
HSCR associated SNPs determined by a GWAS 8  overlapped a conserved region 
(Figure 7). Of the 38 SNPs that were tested for this project, only 14 were found in 
regions previously determined to be enhancers based only on sequence 
conservation 21  (Table 4). Of these 14 SNPs, 13 proved to have enhancer activity 
and six of them also displayed an allelic difference between the ancestral (non-
risk) and disease associated (risk) alleles. Eight additional SNPs were shown to 
be part of a conserved region in the new conservation analysis but were not tested 
previously (rs788263, rs788260, rs2488278, rs947696, rs10900290, rs3026703, 
rs3026707, rs2505995). Of these SNPs, seven showed enhancer activity and two 
showed allelic differences. In total, evolutionary conservation alone is able to 
detect 20 out of the 36 regions that displayed enhancer activity in this study, and 
eight of the 10 SNPs that show an allelic difference. However, of the remaining 16 
SNPs not mapping to previously reported enhancer regions or ECR, 15 had 
enhancer activity and two displayed an allelic difference. Thus, sequence 
conservation coupled with the use of enhancer marks (H3K4me1, H3K27ac, and 
DNase Hypersentivity) and disease associated variants can be powerful tools in 
discovering regulatory regions in the genome and creating a more complete 
genomic map. 
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Table 4: SNP location compared to Previously Tested Enhancers 
(PTE) and Evolutionarily Conserved Regions (ECR) 
SNP 










1 rs788267 No No Yes No 
2 rs788263 No Yes  Yes Yes 
3 rs788262 No No Yes No 
4 rs788261 No No Yes Yes 
5 rs788260 No Yes  Yes Yes 
6 rs2995411 No No Yes No 
7 rs1582227 No No Yes No 
8 rs2488278 No Yes  Yes No 
9 rs2506030 Yes  Yes  Yes Yes 
10 rs17158318 No No Yes No 
11 rs17158320 No No Yes No 
12 rs947696 No Yes  No No 
13 rs7908085 No No Yes No 
14 rs10900290 No Yes  Yes No 
15 rs947690 Yes  Yes  No No 
16 rs1547930 Yes  Yes  Yes Yes 
17 rs3004258 No No Yes No 
18 rs4948702 Yes  No Yes No 
19 rs7069590 Yes  Yes  Yes Yes 
20 rs3026703 No Yes  Yes No 
21 rs3026707 No Yes  Yes No 
22 rs2505989 Yes  Yes  Yes No 
23 rs2435367 Yes  No Yes No 
24 rs741763 No No Yes No 
25 rs2505995 No Yes  Yes No 
26 rs2506010 No No Yes No 
27 rs2506011 Yes  Yes  Yes No 
28 rs2506020 No No Yes No 
29 rs2435357 Yes  Yes  Yes Yes 
30 rs2506021 No No Yes No 
31 rs2435342 No No Yes No 
32 rs2506022 No No Yes No 
33 rs2435343 No No Yes No 
34 rs12247456 Yes  Yes  Yes Yes 
35 rs752978 Yes  Yes  Yes No 
36 rs7393733 Yes  Yes  Yes Yes 
37 rs2506024 Yes  No Yes No 
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Figure 7: Evolutionary Conservation at the RET locus (chr10:43,430,437-43,629,595). 
The ECR (evolutionarily conserved regions) track shows regions with at least 70% 
sequence identity over 100 bp across 12 non-human vertebrates. DNA elements that 
acted as enhancers in previous studies were tested based on ECR data are shown in the 
“Previously Tested Enhancers” track. DNA elements that acted as enhancers in this study 
are based on the ~500 bp regions surrounding the HSCR associated SNPs and are shown 
in the “Enhancers in this Study” track. 
 
Haplotype frequencies in control and case populations 
In order to determine how a specific haplotype affects an individual’s 
chance of disease, the odds ratio was calculated. The odds ratio is the ratio of the 
frequency of a haplotype in a population with the disease compared to frequency 
of the haplotype in a control population of the same ethnicity. (Table 5). An odds 
ratio greater than 1 indicates that individuals with the haplotype are more likely 
to have the disease, while an odds ratio of less than 1 indicates that the haplotype 
is protective. The haplotype with one risk allele in it is set to unity (1) and odds 
ratio for other haplotypes were calculated relative to it. Usually the haplotype 
with no risk alleles in it is set to unity, but in this case we selected only haplotypes 
which were present with >1% frequency; the haplotype with no risk allele was not 
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observed. Because of the sample size (220 individuals in the disease population, 
503 individuals in the control population) and varying associations between the 
SNPs, some of the haplotypes aren’t present at all or are present at a very low 
frequency, and, therefore, it is impossible to draw any meaningful conclusions 
about these haplotypes. Our data showed that three haplotypes have a 
statistically significant odds ratio: CTGAGCCGGC (OR: 0.36, P=0.002), 
CTGAGTTGGT (OR: 5.89, P= 2.76x10-5), and GCAGGTTGGT (OR: 11.01, 
P=1.21x10-9) (SNP order 2, 4, 5, 9, 16, 19, 29, 34, 36, 38 with green indicating 
non-risk allele and red indicating risk allele). Understanding the odds ratio  
 








CTGAACCACT 0.02 0.06 1.00 1 
CTGAATCACT 0.03 0.05 2.01 0.246 
CTGAGCCACT 0.03 0.06 1.50 0.078 
CTGAGTCACT 0.03 0.05 2.41 0.427 
CTGAATCGGC 0.06 0.11 1.94 0.147 
CTGAGCCGGC 0.01 0.05 0.36 0.002 
CTGAGTCGGC 0.05 0.14 1.34 0.512 
CTGAATTGGT 0.02 0.02 3.76 0.022 
CTGAGTTGGT 0.12 0.07 5.89 2.76x10-5 
GCAGGCCACT 0.01 0.05 0.81 0.730 
GCAGGTCACT 0.03 0.06 1.84 0.204 
GCAGGTCGGC 0.06 0.10 1.86 0.160 
GCAGGTTGGT 0.54 0.17 11.01 1.21x10-9 
In the haplotypes, the alleles appear in the following order: 2, 4, 5, 9, 16, 19, 29, 34, 36, 38. 
Non-risk alleles are shown in green and risk alleles are shown in red. Odds ratios with 
significant P-values are highlighted in yellow.  
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associated with a specific haplotype can greatly improve the ability to understand 
the combinatorial effect of these non-coding variants.  Additionally, determining 
if the alleles are statistically associated or not (and to what degree) can help us to 
impute the genotype of one SNP based on the genotype of another. We also note  
 
 
Figure 8: Linkage Disequilibrium Map of the ten SNPs displaying an allelic difference, 
shown in the following order: 2, 4, 5, 9, 16, 19, 29, 34, 36, 38. The bar at the top of the figure 
shows the positions of the SNPs relative to each other with the SNP IDs listed 
underneath. The R-squared values are shown at the diagonal intersection of the two 
SNPs. Black squares without an R-squared value indicate a value of 100, or that the two 
SNPs are in perfect linkage disequilibrium. 
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that two alleles can be in high LD can but can be part of two independent 
enhancers and also show allelic difference in expression. For example, rs788263, 
rs788261, and rs788260 are in complete linkage disequilibrium based on the 
samples we analyzed, but are likely independent factors (Figure 8). However, 
when the SNPs were tested in individual vector constructs, they each showed a 
distinct effect on gene expression, indicating that although they are completely 
associated there is a combinatorial effect to their linkage and not a single SNP 
responsible for the entirety of the change in gene expression. 
 
4. Discussion  
There are many susceptibility genes that add to the multifactorial risk of 
HSCR.3 Nevertheless, despite considerable genetic heterogeneity in HSCR, RET 
is the most critical disease gene since deleterious coding variants occur in 21%, 
intragenic deletions in 5%, and enhancer variants in >98% of HSCR patients. 22 
When examining the haplotypes present in control and case populations in this 
study, it becomes evident that most humans carry a non-coding RET deficiency 
allele since no individuals with all non-risk alleles were identified (Table 5). 
Furthermore, 17% of the individuals in the control population (i.e. individuals 
that do not have HSCR) have a haplotype that consists entirely of HSCR-
associated risk alleles. Despite harboring a haplotype increasing the odds of 
developing HSCR 11-fold, it is still possible for individuals to be unaffected. 
Therefore, RET deficiency per se is necessary, not sufficient, for disease onset. 
In the recent past, thousands of genetic variants affecting hundreds of 
traits and diseases have been discovered through GWAS. 23 Despite widespread 
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non-coding polymorphisms, multiple enhancers controlling each gene, and 
enrichment of disease association signals within such enhancers, there has been a 
distint lack of effort to do a comprehensive functional screen of all such variants 
even at a single locus. Therefore, we still do not know how many enhacers a gene 
can have, how many affect expression in a specific cell type, how many of these 
enhancers are mutant in human disease and how do they lead to disease given 
their individual weak effects. 
Of a comprehensive functional assay of 30 HSCR associated SNPs, we 
found 28 of them are part of distinct loci with enhancer ability. Furthermore, 
seven of those SNPs exhibited an allelic difference between the non-risk and risk 
alleles and therefore potentially disrupt RET transcription and contribute to the 
development of HSCR.  Testing all of the variants individually allowed us to 
construct haplotypes containing alleles displaying disruption of enhancer 
function. From this, we were able to calculate disease risk for various haplotypes, 
thus highlighting the importance of the combinatorial effect of the individual 
variants on the disease risk since none of the identified SNPs cause the disease on 
their own. 
This study also determined several transcription factors are candidate 
regulators of some of the enhancers at RET and whose binding might be 
disrupted by the SNPs displaying an allelic difference. The identification of 
putative TF binding sites opens the possibility of understanding the regulation of 
RET in vivo in a more detailed manner, including its upstream regulators as well 
as allowing us to build gene regulatory networks (GRNs) containing RET and its 
associated functional partners, which can explain how the disruption of an 
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enhancer by a SNP might have a larger than expected effect on gene expression 
due to disruption of the GRN as a whole. 
It is important to note that some of the SNPs tested in this study are 
clustered in such a way that they could be part of the same enhancer element or a 
part of a super enhancer.17 Additionally, the combinatorial effects of the 
enhancers may not be fully appreciated. In vivo, enhancer elements act 
dynamically and combinatorially and are generally within large regulatory 
domains called topologically associated domains (TADs). 25 By testing the regions 
individually, any in vivo associations within a TAD would have been eliminated. 
Thus, a complete understanding of the genetic effect of a non-coding variant on a 
gene or disease requires knowledge of its multiple enhancers, how the target gene 
interacts with these enhancers, and if the SNPs cause a disruption of its GRN.  
Identifying all causal SNPs is imperative to understand the complexity of a 
multifactorial disorder, and it may also give us mechanistic insights in to the 
progression of the disease. Combining knowledge from forward genetic screens 
with functional validation of the role of various TFs will help in better predicting 
the consequences of various non-coding variants associated with a disease 
Limitations 
There are a few limitations that are important to consider regarding the 
results of this study. The first is that while the in vitro luciferase assay does test 
for enhancer activity, there is no direct proof that these are enhancers of RET. In 
humans, enhancers can be either upstream or downstream of the target gene, and 
they can also be 1 Mb or more distal. 26  So, even if a construct DNA segment is 
shown to be an enhancer in a heterologous assay, there is no guarantee that it 
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regulates RET or that SNPs with differential allelic activity leads to effect on the 
transcription of the gene. These regions of DNA will need to be evaluated by 
either deleting or creating the exact variant in a model organism to ascertain how 
they impact the transcription of RET, and in turn the differentiation and 
proliferation of enteric neurons.  
The second limitation is about the nature of the control experiment we 
utilized. When fragments of DNA are inserted into the pGL4.23 [luc2/minP] 
vector, the assay can determine if there are any sequences within the larger 
fragment that can drive gene expression. However, this is being compared to an 
empty vector, or a pGL4.23 vector with nothing inserted into its multiple cloning 
site. Because of this, the empty vector is ~500 bp smaller than vectors with an 
insert. This represents a ~10% size change with an enhancer fragment inserted. It 
is quite likely that any piece of DNA can drive some transcription so that an 
effective control is difficult to define for the cloning step. However, it is 
impossible to determine if the size of the vector with the insert changes anything 
compared to the empty vector such as transfection efficacy, etc.   
Finally, there are always limitations when using cell culture to model in 
vivo cellular functions. SK-N-SH human neuroblastoma cells were used for these 
assays because a human neuronal cell line likely has somewhat similar gene 
expression patterns compared with human fetal enteric neuron cells. However, 
fetal cells and adult cells are markedly different developmentally and it is 
possible for fetal gut cells to express TFs that SK-N-SH cells do not, or vice versa. 
The transcription machinery in the SK-N-SH cells are responsible for all of the 
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data for this study, so considerations should be made when generalizing the 
results to in vivo conditions.  
Future Directions 
Since enhancers in vivo work dynamically and combinatorially, the SNPs 
need to be tested together in order to more closely model their actual effect on 
gene expression in vitro. A multiple mutant construct could be made to mirror 
the haplotypes found in the human population and then used in gene expression 
assays similar to those used in this study. Although this would still suffer from 
the limitations associated with in vitro experiments, it would create a more 
complete picture of the total effect of the enhancer regions. 
Causative SNPs most likely disrupt TF binding sites and therefore affect 
gene expression. Although TF binding motif databases exist, they are predictive 
and require further experimental validation. The best way to do this would be to 
perform a TF-ChIP experiment for various putative TFs determined to bind 
sequence prediciton at the RET locus in vivo (in this case, in human fetal gut 
cells). This would eliminate the uncertainty of whether or not a TF is present in 
the cells at the time of development as well as the uncertainty of the TF binding 
domain.  
Conclusion 
 HSCR is a complex disease with multifactorial inheritance. Despite its 
relatively high occurrence rate, the genetic basis of HSCR is still not completely 
identified. Mutations in RET have been implicated as the major genetic cause of 
HSCR. This study examined 38 SNPs associated with HSCR and identified 36 
putative enhancer regions and 10 potentially causative SNPs at the RET locus. 
	   28	  
Identifying all causative SNPs will greatly enhance the predictive power of genetic 
tests for HSCR as well as advance an understanding of how the disease develops. 
The putative enhancer elements and potentially causative SNPs identified in this 
study contribute to the development of a complete regulatory map of the RET 
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5. Appendix 
 
Appendix Table 1: ~500 bp regions of DNA surrounding each SNP are shown. Rows 
that are greyed out are SNPs that were previously characterized and therefore not 
included in this study. The “Start” and “Stop” columns refer to the chromosomal 
coordinates where the fragment surrounding the SNP begins and ends. All 38 SNPs are 
found in the RET locus on chromosome 10. 
SNP # SNP ID Start Stop 
1 rs788267 43434932 43435936 
2 rs788263 43437007 43437506 
3 rs788262 43437440 43437943 
4 rs788261 43437726 43438225 
5 rs788260 43438228 43438727 
6 rs2995411 43440554 43441053 
7 rs1582227 43441446 43441952 
8 rs2488278 43446082 43446581 
9 rs2506030     
10 rs17158318 43448581 43449090 
11 rs17158320 * included with SNP 10 in a single vector 
12 rs947696 43455083 43455582 
13 rs7908085 43460567 43461065 
14 rs10900290 43471322 43471823 
15 rs947690 43479479 43479979 
16 rs1547930 43483056 43483559 
17 rs3004258 43483900 43484403 
18 rs4948702     
19 rs7069590     
20 rs3026703 43557546 43558048 
21 rs3026707 43558368 43559122 
22 rs2505989 43563195 43563700 
23 rs2435367     
24 rs741763 43568087 43568586 
25 rs2505995 43569379 43569878 
26 rs2506010 43573167 43574025 
27 rs2506011     
28 rs2506020 43578754 43579373 
29 rs2435357     
30 rs2506021 43583869 43584408 
31 rs2435342 * included with SNP 30 in a single vector 
32 rs2506022 43584264 43584845 
33 rs2435343 43585384 43585889 
34 rs12247456 43587982 43588420 
35 rs752978     
36 rs7393733 43588440 43588915 
37 rs2506024     
38 rs2505541 43589862 43590368 
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Appendix Table 2: Forward and Reverse primer sequences for the ~500 bp regions 
surrounding the SNPs listed in Appendix Table 1. The primers shaded in grey are 
primers that I already had from a previous project, and were cloned by double cutting 
with KpnI-HF and SacI-HF in CutSmart Buffer and ligating with T4 DNA Ligase rather 
than homologous recombination. TGGCCTAACTGGCCG was added to the 5’ end of all 
forward primers as the 15 bp homology arm and TCTTGATATCCTCGA was added to the 
5’ end of all reverse primers as the 15 bp homology arm.  
SNP 
# SNP ID Forward Primer (5'-3') Reverse Primer (5'-3') 
1 rs788267 CCAATAGGCAGGCAAGACAC GACCCACTGAAGTCTGGAGG 
2 rs788263 CACTCTCGCTCCCTCATTTG CCCTCAGAGTCTGGGCAGT 
3 rs788262 GAACCTCCCTAGCCAGTTCC GTTCCTCATCCTGCTCCTGT 
4 rs788261 GCACATGCATGGAGAACTGT CTCTGCTGGGCTATCTGGAG 
5 rs788260 GCGGAGACAAGATGATCCA TGCTGAAAAGCCTCTTTGGT 
6 rs2995411 AGGCAGGAGAATAGCGTGAA TGCTATGACTTCTTGGTGGGT 
7 rs1582227 CTCCTGACTTCGTGATCTGC TCCCTCTTCTGTGATGTAGGC 
8 rs2488278 CTGCCGGTTCTTGGTTTTT GGCTCCTCCTTGGTGCTTAT 
10 rs17158318 TGCTCTACCATTTCCGCAGA ACACACAGCATCCTCTCTCC 
11 rs17158320 * included with SNP 10 in a single vector 
12 rs947696 AGGTACCTAGCTCACCATGT ATAGCTGGGATCATAGGCCC 
13 rs7908085 TCTTTCATTCCAATCTGCATGTC TCAGCAAATCAAATTCAGCAACA 
14 rs10900290 CCTGATGACCCCTGCTTTCA TGCCTCAATCTTACCTGCCA 
15 rs947690 TCCTGTGGTATGATGGTGCA ACGGGAGCAATGTTCTGGAG 
16 rs1547930 AGCTCCCTGAAGTCACGTTA GAATTCACAGGCCAGCTTCC 
17 rs3004258 TGAGCGCTTTCCTTCTCAGA ACAGAGGTCACAGGGTTCAG 
20 rs3026703 GGTCTAGTCTCGCTGTGCTA GCTGTTGTTGACTGTCGGTT 
21 rs3026707 ATCCCTCCTGCAGATCTGTG CAGCCCTCATCTCCAACTGA 
22 rs2505989 ATCAACATGGAGGCCTGGAA AGCTTCTCCTTCCGGCTTAG 
24 rs741763 GACAAGAGACAGAGCGCAGA TTCAGAGAAAGCCCACCTCC 
25 rs2505995 ACAGGAAGATGGTGTGAGCC GGAGAATCTTCAGGGCAGCT 
26 rs2506010 CCGCCCTGTCTTTAAACACC CCATGGCTTCTTCTGTTCCC 
28 rs2506020 TGTCCTTCTTGTGGCATAGC CAATGCCTGTTCAATGCTGT 
30 rs2506021 GTAGTGGAGGTGATGGTGCT AGGTGAATGCTGGTTGGAGA 
31 rs2435342 * included with SNP 30 in a single vector 
32 rs2506022 CCTCTACCTCCTGCTGCTTT CTGCTGGCCAAGAAAACAGG 
33 rs2435343 CCTGAGAGTTAAGGGAGGCA ATTCCCTGTGTCTTCCCTGC 
34 rs12247456 GCCTCCCTTGATCCGTGT TGGTCAGAATTTGGGAAGGG 
36 rs7393733 CCATTGTACTGGCTCGTTGA CTTCCCCATCTCATCACGGT 
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Appendix Table 3: HapMap Samples used as template DNA for each construct.  





1 rs788267 NA19445 NA19430 
2 rs788263 NA07056 NA06986 
3 rs788262 NA19445 NA21118 
4 rs788261 NA07056 NA06986 
5 rs788260 NA07056 NA06986 
6 rs2995411 NA21118 NA19445 
7 rs1582227 NA21118 NA19445 
8 rs2488278 NA07056 NA06986 
10 rs17158318 NA21118 NA19445 
11 rs17158320 NA21118 NA19445 
12 rs947696 NA21118 NA19445 
13 rs7908085 NA20585 NA19445 
14 rs10900290 NA19445 NA21118 
15 rs947690 NA21118 NA19445 
16 rs1547930 NA21118 NA19445 
17 rs3004258 NA19445 NA21118 
20 rs3026703 NA21118 NA19445 
21 rs3026707 NA21118 NA18520 
22 rs2505989 NA21118 NA11830 
24 rs741763 NA19445 NA11830 
25 rs2505995 NA21118 NA19445 
26 rs2506010 NA19445 NA11830 
28 rs2506020 NA21118 NA19445 
30 rs2506021 NA19445 NA11830 
31 rs2435342 NA19445 NA11830 
32 rs2506022 NA19445 NA11830 
33 rs2435343 NA19445 NA11830 
34 rs12247456 NA19445 NA19434 
36 rs7393733 NA19445 NA19434 
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• Spring 2016: General Biology Lab Teaching Assistant at The Johns Hopkins 
University – Dr. Rebecca Pearlman 
Ø Independently led a three-hour lab for 15 students weekly 
Ø Responsible for all grading 
Ø Met with other TAs weekly to discuss lab goals and expectations 
Ø Assisted with proctoring and grading for General Biology II lecture course  
COMMUNITY SERVICE EXPERIENCE 
• 2012-2016: Volunteer at Johns Hopkins University President’s Day of Service 
Ø Annual day-long volunteer experience to benefit the Baltimore community 
Ø Projects have ranged from river cleanups to paining elementary school 
classrooms 
Ø Learned about some needs of the local community 
• 2013-2016: Volunteer at Art of Caring for Court Appointed Special Advocates 
(CASA) 
Ø Annual afternoon-long silent art auction 
Ø Have assisted with set up, check in, and bidding 
• July 2015: Volunteer at The Kapiolani Women’s Center 
Ø Short term volunteer position (24 hours over the course of three weeks) 
Ø Performed data collection for a best practice study on breast tomosynthesis  
Ø Assisted with administrative tasks related to an annual Christmas party for breast 
cancer survivors 
• January 2016-Present: Intern at A Woman’s Journey (AWJ) – Johns Hopkins 
Medicine 
Ø 4 hours a week 
Ø Volunteered at the day-long Baltimore conference in November 2015 as a room 
docent (attended and monitored four breakout sessions and a lunch plenary 
session) 
Ø Assisted with planning and preparation for the eight annual women’s health 
conferences as well as the annual Executive Women’s Breakfast 
Ø Wrote an article on preventive tests to be included in the AWJ program 
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LEADERSHIP EXPERIENCE 
• November 2013-December 2014: Chief Administrative Officer (CAO) of the Zeta Chi 
Chapter of Kappa Alpha Theta Fraternity 
Ø Responsible for all general mechanics of the chapter 
Ø In charge of the chapter calendar, correspondence, and other functional 
necessities 
Ø Created a weekly update containing information gathered from all other officers 
through regular communication 
Ø Planned and executed a workshop (L.E.A.D. - Lead. Empower. Aspire. Develop.) 
for all officers 
Ø Oversaw chapter elections and officer transitions 
Ø Managed chapter roster  
Ø Attended weekly Executive Board meetings  
• Fall 2013-Spring 2015: Senior Event Coordinator for the JHU Hawai’i ‘Ohana Club 
Ø Responsible for scheduling all club events and reserving classroom spaces 
Ø Assisted in planning the annual lu’au, freshman bonding event, and club bonding 
events  
• Fall 2015-Spring 2016: Vice President for the JHU Hawai’i ‘Ohana Club 
Ø Worked with other student groups to expand the annual lu’au 
Ø Discussing the implementation of an educational event to explain the cultural 
“mixing pot” identity of Hawai’i 
SKILLS 
• Proficiency in Microsoft Word, Excel, PowerPoint 
• Basic knowledge of Adobe Photoshop 
• Limited Working Proficiency in Japanese 
• Able to work in a Biology wet lab environment 
• Excellent communication skills  
 
 
